You thought VRX buying you was the worst thing, now look....

Discussion in 'Allergan' started by Anonymous, Nov 18, 2014 at 7:41 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    "Still, many of Allergan’s scientists will be hoping that the “anyone but Valeant” strategy has not ended up with (Activas) the company selling itself to a milder version of the same thing."
     

  2. Anonymous

    Anonymous Guest

    It is less bad. Actavis plans only $450M in R&D cuts vs the $900M that Valeant was talking.
     
  3. Anonymous

    Anonymous Guest

    But just as many total people will lose their jobs. Valeant claimed 2.7B in "synergies" Actavis is claiming 1.8B.

    the difference between the two company's tax rates - Irish versus effective Canadian applied to Allergan's Revenues is ~850MM

    The "human capital" being cut in both scenarios is almost identical. Plan on about 30% of all Allergan employees being let go. That's on top of the 13% earlier this year (though some of that 13% was pencil pushing open position cuts) about 8% of real employees were cut.

    So, when it's all said and done 35-40% of our colleagues and ourselves will be out of a job.
     
  4. Anonymous

    Anonymous Guest

    VRX was planning a 65% work force reduction.
     
  5. Anonymous

    Anonymous Guest


    That is SUCH an incredible lie.

    Irvine is left open and it's going to effectively be specialty pharma in irvine and primary and generics business in New Jersey

    This is going to be an amazing company
     
  6. Anonymous

    Anonymous Guest

    It's not a lie, it's math.

    You think Brent Saunders got up in front of wall street and just pulled that 1.8B number from his arse?

    How exactly do you think he plans on finding those "synergies" 450million in R&D, he already flat out said it. So the other 1.4B comes from where smart guy?

    Tax rate saves a fixed amount. Everything after that = people.

    Or, you explain the math.
     
  7. Anonymous

    Anonymous Guest

    I agree this will be a great company but that doesn't necessarily mean that all the reps will be brought along. The rest od the Synergies will come from corporate overlap/IT etc and sales force reductions....FROM BOTH SIDES. Actavis is still heavy sales force wise and now you add on Allergan....cuts will be coming.
     
  8. Anonymous

    Anonymous Guest

    Valeant is still a "House of Cards" from an accounting point of view. Any company is better than Valeant if you remember Enron or Tyco, who were both darlings of Wall Street until the smoke and mirrors came crashing down.

    Being owned by a company like Valeant who is on borrowed-time and always just one more merger away from not being able to cover its debts, is just not a future anyone wanted. Valeant is not a company, its an accounting bubble that no one knows when it will pop!
     
  9. Anonymous

    Anonymous Guest

    Simple. The operating costs, and market cap, of this combined company is significantly greater to subtract 1.8 from than a VRX/AGN combined company - 2.7. Especially since the 2.7 would come from R&D, and Irvine versus the 1.8 coming from overlapping costs, yes some sales force redundancies

    Hypothetically if the act/agn operating costs is 8 - 1.8 is pretty good with that 1.8 being equally distributed on a "best of the best" model versus a 6 - 2.7 with most of that 2.7 coming from Allergan

    We know that there will be a combkned mgmt team, we know irvine will stay open, we know there is belief in R&D and there is much more of a global footprint to trim from versus the valeant "decentralized" model.

    We also know that enhanced severance is built in, etc

    Soooo much better on so many levels unless you are a VRX shareholder or troll
     
  10. Anonymous

    Anonymous Guest

    Gee, I feel a whole lot better now.
     
  11. Anonymous

    Anonymous Guest

    White Knight...? LOL Just wait, White Knight will turn into donkey....
     
  12. Anonymous

    Anonymous Guest

    More like White Castle
     
  13. Anonymous

    Anonymous Guest

    It the Town hall the maths was all wrong Act has 25000 people allergan has 11 the new company will have 30000 where are the rest going?
     
  14. Anonymous

    Anonymous Guest

    "best of the best" was language used at bausch and lomb acquisition from ista aka. Brent Saunders. They laid off the bottom 50% reps from both companies. Whichever rep in that area had the better numbers, that's who stayed.
     
  15. Anonymous

    Anonymous Guest

    I don't think VRX would have been better, but at least there was enough "history" on how they treat rep after they are bought. I am told to make clients believe "business as usual", but aesthetic doc don't know who ACT is. My integrity is on the line so I hope ACT doesn't change the way we dis business at AGN!
     
  16. Anonymous

    Anonymous Guest

    OMG, a rep just said their 'integrity' is on the line.
     
  17. Anonymous

    Anonymous Guest



    What do you mean? They will all be SH!t-canned!
     
  18. Anonymous

    Anonymous Guest

    Big cuts are going to come all over. Who are we kidding- we don't have much of a pipeline (so much for the billions we spend on R&D) and they have plenty of sales representatives and management.

    The writing is on the wall. Don't be blind.
     
  19. Anonymous

    Anonymous Guest

    the writing doesn't have to be "on the wall" dumbfuck - we're being acquired and it's general knowledge there will be significant cuts across the board

    But thanks for leveling with everyone, you really know your stuff.
     
  20. Anonymous

    Anonymous Guest

    Cut announcement was on the stock ticker today.